Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

(2017) F Passamonti et al.   LEUKEMIA

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis

(2017) Lucia Masarova et al.   LEUKEMIA RESEARCH

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups

(2015) H. Joachim Deeg et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients

(2015) Mads Emil Bjørn et al.   LEUKEMIA & LYMPHOMA

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis

(2015) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

(2014) J.-C. Hernandez-Boluda et al.   HAEMATOLOGICA

Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

(2013) R. Luthra et al.   HAEMATOLOGICA

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

(2013) Moshe Talpaz et al.   Journal of Hematology & Oncology

Guideline for the diagnosis and management of myelofibrosis

(2012) John T. Reilly et al.   BRITISH JOURNAL OF HAEMATOLOGY

Leukemia risk models in primary myelofibrosis: an International Working Group study

(2012) A Tefferi et al.   LEUKEMIA

The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis

(2012) Umberto Gianelli et al.   MODERN PATHOLOGY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival

(2009) Mrinal M. Patnaik et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

(2009) Constantine S. Tam et al.   JOURNAL OF CLINICAL ONCOLOGY

Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence

(2008) J.-J. Lataillade et al.   BLOOD